Correction: Increased Levels of Plasma Soluble Sema4D in Patients with Heart Failure

There are errors in Fig 5 and Fig 6. Please see the correct Fig 5 and Fig 6 here.

Fig 5. Sema4D expression on lymphocytes in HF patients and healthy donors.

Fresh PBMCs from HF patients and healthy donors were double-stained and analyzed by FACS. The region corresponding to lymphocytes (R1) was selected using an FSC-H/SSC-H density plot. Using an FITC-density plot applied to the R1 region, the regions R2 and R3 corresponding to CD3⁺ and CD19⁺ cells, respectively, were defined (upper panels of 5A and 5B). In the PE density plot (middle panels of 5A and 5B), the right region delimits CD3⁺ and CD19⁺ cells with high expression of Sema4D, respectively. PE-conjugated IgG was used as an isotypic control. The percentage of Sema4D^high CD3⁺ cells and Sema4D^high CD19⁺ cells in healthy donors (HD) and HF patients (HF) were analyzed (lower panels of 5A and 5B). P values were obtained using ANOVA followed by a Tukey post test.

Fig 6. Sema4D expression on T cell subpopulations in HF patients and healthy donors.

Fresh PBMCs from HF patients and healthy donors were double-stained and analyzed by FACS. The region corresponding to lymphocytes (R1) was selected using an FSC-H/SSC-H density plot. Using a FITC-density plot applied to the R1 region, the regions R4 and R5 corresponding to CD4⁺ and CD8⁺ cells, respectively, were defined (upper panels of 6A and 6B). In the PE density plot (middle panels of 6A and 6B), the right region delimits CD4⁺ and CD8⁺ cells with high expression of Sema4D, respectively. PE-conjugated IgG was used as an isotypic control. The percentage of Sema4D^high CD4⁺ cells and Sema4D^high CD8⁺ cells in healthy donors (HD) and HF patients (HF) were analyzed (lower panels of 6A and 6B). P values were obtained using ANOVA followed by a Tukey post test.